XOMA Ltd.
2910 Seventh Street
Berkeley,
CA 94710
United States - Map
Phone: 510-204-7200
Fax: 510-644-2011
Web Site: http://www.xoma.com
| XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases. The company receives royalties on three approved products: RAPTIVA, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis; LUCENTIS, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration; and CIMZIA, which is approved in the U.S. and Switzerland for the treatment of Crohns disease. Its products under development include XOMA 052, a monoclonal antibody for the treatment of Type 2 diabetes, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and gout, which is in Phase 1 clinical studies; and XOMA 3AB, a biodefense anti-botulism antibody for the treatment of botulism poisoning. The companys developing products also include HCD122, a human anti-CD40 antagonist antibody for the treatment for B-cell mediated diseases, including malignancies and autoimmune diseases in Phase 1 and Phase 2 clinical trials for various indications. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Genentech, Inc.; UCB Celltech; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Schering-Plough Research Institute; Novartis AG; and Arana Therapeutics Limited. XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Steven B. Engle , 54
Chairman, Chief Exec. Officer and Pres |
$
515.00K |
$
0 | Dr. Patrick J. Scannon M.D., Ph.D., 61
Founder, Chief Medical Officer, Exec. VP |
$
370.00K |
$
0 | Mr. Fred Kurland , 58
Chief Financial Officer and VP of Fin. |
$
0 |
$
0 | Mr. Robert S. Tenerowicz , 46
VP of Operations and Head of the Biodefense business unit |
$
270.00K |
$
0 | Mr. Christopher J. Margolin Esq., 62
VP, Sec., Gen. Counsel and Head of the Technology Licensing Bus. Unit |
$
322.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.002 (0.27%) 
Profile
